<DOC>
	<DOCNO>NCT01568489</DOCNO>
	<brief_summary>The objective phase 2 study evaluate safety efficacy HL-009 Liposomal Gel adult patient mild moderate atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Phase 2 Study HL-009 Liposomal Gel Treat Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group comparison study subject mild moderate AD . Following 2-week screening period , subject randomly assign one four treatment arm . Placebo HL-009 study treatment administrate subject twice daily 8 consecutive week . After randomization Week 0 ( Visit 2 ) , subject visit respective trial site Weeks 0.5 , 1 , 2 , 4 , 6 , 8 , 10 ( Visits 3 , 4 , 5 , 6 , 7 , 8 , 9 ) . All study drug identical laminate tubes preserve double-blinding study .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Males female age 18 old Clinical diagnosis AD board certified/eligible dermatologist Subjects body surface area affect least 2 % total body surface area ( BSA ) Subjects IGA score 2 3 correspond mild moderate AD screening baseline visit Subjects give write informed consent Subjects topical treatment corticosteroid within 2 week screen Subjects systemic treatment corticosteroid ciclosporin photopheresis treatment within 2 week screen Subjects ultraviolet irradiation within 2 week screen Subjects participate another drug trial within 4 week screen Subjects allergy one excipients Female subject positive serum pregnancy test screening , plan pregnancy study period , breast feed Female subject n't meet one follow criterion : Be surgically sterile , Postmenopausal least 12 month , If sexually active , use oral contraceptive , double barrier contraception , intrauterine device , method approve sponsor Subjects topical treatment AD area Subjects take systemic antiinfective antibiotic treatment Subjects eczema herpeticum Subjects clinically significant presence skin disease pigmentation atopic dermatitis , wide scar atopic dermatitis area Subjects poorlycontrolled chronic disease Subjects significant medical problem , include limited uncontrolled hypertension congestive heart failure Subjects clinically significant laboratory abnormality screen Subjects mark prolongation QT/QTc interval screen Subjects history additional risk factor TdP Subjects use medication prolongs QT/QTc interval Subjects , opinion investigator , would noncompliant visit schedule study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>